Onyx Biotec Ltd. has entered into a manufacturing agreement with Galpha Laboratories Limited for the production of Dry Powder Injection.

This collaboration aims to enhance Onyx's product offerings in the biopharmaceutical market.

The agreement does not involve any shareholding connection between the two parties, nor does it classify as a related party transaction.

This development reflects Onyx's strategy to expand its manufacturing capabilities and align with industry needs.

Investors should view this partnership as a potential growth opportunity, positioning Onyx to leverage Galpha’s expertise in the production process, contributing positively to its operational scope and market competitiveness.